Anaplastic myeloma.
Anaplastic myeloma (AM) represents a rare variety of multiple myeloma (MM) with poor prognosis. One case with special interest is reported, which presented with manifestations due to the extramedullary localization and arose in the absence of an initial diagnosis of MM. In addition, differential diagnosis was based on morphological and immunocytochemical findings while treatment with radio-chemotherapy had no effect on the extramedullary sites.
Zervas
K
K
Haematology Department, Cancer Hospital, Theaganion, Thessaloniki, Greece.
Constantinou
N
N
Karakantza
M
M
Tsigalidou-Balla
V
V
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D008875:Middle Aged; D008940:Mitotic Index; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D009363:Neoplasm Proteins / Q000032:analysis; D014411:Neoplastic Stem Cells / Q000473:pathology; D015260:Neprilysin / Q000032:analysis; D011241:Prednisone / Q000008:administration & dosage; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D014750:Vincristine / Q000008:administration & dosage
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D015260:Neprilysin; D011241:Prednisone